A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer by Capalbo, Carlo et al.
cancers
Article
A Simplified Genomic Profiling Approach Predicts
Outcome in Metastatic Colorectal Cancer
Carlo Capalbo 1,2,†, Francesca Belardinilli 1,†, Domenico Raimondo 1, Edoardo Milanetti 3,
Umberto Malapelle 4, Pasquale Pisapia 4 , Valentina Magri 5, Alessandra Prete 5,
Silvia Pecorari 5, Mariarosaria Colella 1, Anna Coppa 6 , Caterina Bonfiglio 7,
Arianna Nicolussi 6, Virginia Valentini 1, Alessandra Tessitore 8, Beatrice Cardinali 9 ,
Marialaura Petroni 10, Paola Infante 10, Matteo Santoni 11, Marco Filetti 2, Valeria Colicchia 1,
Paola Paci 12 , Silvia Mezi 5, Flavia Longo 5, Enrico Cortesi 5, Paolo Marchetti 2,
Giancarlo Troncone 4, Diana Bellavia 1, Gianluca Canettieri 1,13,*,† and
Giuseppe Giannini 1,13,*,†
1 Department of Molecular Medicine, University La Sapienza, 00161 Rome, Italy;
carlo.capalbo@uniroma1.it (C.C.); francesca.belardinilli@uniroma1.it (F.B.);
domenico.raimondo@uniroma1.it (D.R.); colella.1624422@studenti.uniroma1.it (M.C.);
virginia.valentini@uniroma1.it (V.V.); valeria.colicchia@uniroma1.it (V.C.); diana.bellavia@uniroma1.it (D.B.)
2 Department of Medical Oncology Sant’ Andrea Hospital, I-00189 Rome, Italy;
marco.filetti@uniroma1.it (M.F.); paolo.marchetti@uniroma1.it (P.M.)
3 Department of Physics, University La Sapienza, 00185 Rome, Italy; edoardo.milanetti@uniroma1.it
4 Department of Public Health, University Federico II, 80131 Naples, Italy;
umberto.malapelle@unina.it (U.M.); pasquale.pisapia@unina.it (P.P.); giancarlo.troncone@unina.it (G.T.)
5 Department of Radiological Oncological and Pathological Sciences, University La Sapienza, 00161 Rome,
Italy; valentina.magri@uniroma1.it (V.M.); alessandra.prete@uniroma1.it (A.P.);
silvia.pecorari@uniroma1.it (S.P.); silvia.mezi@uniroma1.it (S.M.); flavia.longo@uniroma1.it (F.L.);
enrico.cortesi@uniroma1.it (E.C.)
6 Department of Experimental Medicine, University La Sapienza, 00161 Rome, Italy;
anna.coppa@uniroma1.it (A.C.); arianna.nicolussi@uniroma1.it (A.N.)
7 National Institute of Gastroenterology-Research Hospital, IRCCS “S. de Bellis”, Castellana Grotte, 70013 Bari,
Italy; catia.bonfiglio@irccsdebellis.it
8 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy;
alessandra.tessitore@univaq.it
9 Institute of Cell Biology and Neurobiology, National Research Council, Campus A. Buzzati-Traverso,
00015 Monterotondo Scalo, Italy; beatrice.cardinali@cnr.it
10 Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, 00161 Rome, Italy;
marialaura.petroni@iit.it (M.P.); paola.infante@iit.it (P.I.);
11 Oncology Unit, Macerata Hospital, 62012 Macerata, Italy; mattymo@alice.it
12 Institute for Systems Analysis and Computer Science “Antonio Ruberti”, National Research Council,
00185 Rome, Italy; paola.paci@iasi.cnr.it
13 Pasteur Institute-Cenci Bolognetti Foundation, 00161 Rome, Italy
* Correspondence: gianluca.canettieri@uniroma1.it (G.C.); giuseppe.giannini@uniroma1.it (G.G.);
Tel.: +39-06-49255130 (G.C.); +39-06-49255136 (G.G.); Fax: +39-06-49255660 (G.C. & G.G.)
† These two authors equally contributed to the work.
Received: 24 December 2018; Accepted: 22 January 2019; Published: 27 January 2019


Abstract: The response of metastatic colorectal cancer (mCRC) to the first-line conventional
combination therapy is highly variable, reflecting the elevated heterogeneity of the disease. The
genetic alterations underlying this heterogeneity have been thoroughly characterized through omic
approaches requiring elevated efforts and costs. In order to translate the knowledge of CRC molecular
heterogeneity into a practical clinical approach, we utilized a simplified Next Generation Sequencing
(NGS) based platform to screen a cohort of 77 patients treated with first-line conventional therapy.
Samples were sequenced using a panel of hotspots and targeted regions of 22 genes commonly
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involved in CRC. This revealed 51 patients carrying actionable gene mutations, 22 of which carried
druggable alterations. These mutations were frequently associated with additional genetic alterations.
To take into account this molecular complexity and assisted by an unbiased bioinformatic analysis,
we defined three subgroups of patients carrying distinct molecular patterns. We demonstrated
these three molecular subgroups are associated with a different response to first-line conventional
combination therapies. The best outcome was achieved in patients exclusively carrying mutations on
TP53 and/or RAS genes. By contrast, in patients carrying mutations in any of the other genes, alone
or associated with mutations of TP53/RAS, the expected response is much worse compared to patients
with exclusive TP53/RAS mutations. Additionally, our data indicate that the standard approach has
limited efficacy in patients without any mutations in the genes included in the panel. In conclusion,
we identified a reliable and easy-to-use approach for a simplified molecular-based stratification of
mCRC patients that predicts the efficacy of the first-line conventional combination therapy.
Keywords: precision medicine; predictive; NGS; genomic profiling; chemotherapy
1. Introduction
Metastatic Colorectal Cancer (mCRC) is a major burden worldwide, with a 5-year survival rate
of about 13% [1,2]. Currently, standard chemotherapy includes oxaliplatin-based (FOLFOX) and
irinotecan-based (FOLFIRI) regimens, which appear equivalent in efficacy and activity [3,4] allowing a
median overall survival (OS) of about 18–20 months. A significant therapeutic improvement in the
upfront treatment of mCRC can be achieved by a “triplet” approach consisting of 5-FU, platinum and
irinotecan-based chemotherapy (FOLFOXIRI) [5]. The addition of targeted drugs, such as monoclonal
antibodies directed against VEGF (Bevacizumab) or EGFR (Cetuximab and Panitumumab) have
increased the median OS up to 30 months [6–9]. Importantly, KRAS and NRAS (RAS) gene mutations
confer innate resistance to anti-EGFR therapy [10,11]. Consequently, screening for RAS mutations is
now mandatory for first-line therapeutic decisions. Of interest, two large studies (FIRE-3 and PEAK)
indicated the absence of significant differences in the outcome of RAS wild-type mCRC patients
undergoing first-line treatment with either bevacizumab or anti-EGFR added to FOLFOX or FOLFIRI
regimens [12,13]. Thus, while the choice of the most appropriate first line therapy is extremely
important for the general outcome of any cancer patient, available treatments appear substantially
equivalent for RAS wild-type mCRC patients in the clinical routine, where decisions also need to take
into account the patient’s clinical features (performance, age and comorbidities), toxicity issues and
treatment intent. To this end, an evidence-based algorithm for first-line chemotherapy decision-making
in mCRC has been proposed [14].
Of relevance, the response to these standard therapeutic approaches differs from patient to patient,
largely reflecting the clinical heterogeneity of the disease, and leading to a yet unsatisfactory OS rate
of mCRC patients. This is most likely related to the broad intertumor and intratumor molecular
heterogeneity, which has been ascertained by global and integrated Next Generation Sequencing
(NGS)-based genomic and transcriptomic profiling [15–18]. To rationalize this heterogeneity, these
efforts have recently converged on the definition four main consensus molecular subgroups (CMSs):
CMS1 (MSI immune); CMS2 (canonical); CMS3 (metabolic) and CMS4 (mesenchymal) [16], each of
which contains multiple actionable targets.
The recent experience with anti-EGFR treatment and the poor response to PI3K inhibitors [19]
clearly suggests that a better stratification of patients according to specific molecular biomarkers may
dramatically improve the efficacy of targeted therapies, and perhaps also chemotherapy. Nonetheless,
beside RAS gene mutations, and BRAFV600E mutation (for which a prognostic and a predictive
significance have been established [20–22]) the prognostic/predictive value of mutations in other
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genes (i.e., TP53, or PIK3CA) is still unclear and no predictive markers are yet available for the response
to VEGF inhibitors [23,24].
Thus, despite the substantial advances in understanding the molecular basis of this disease,
how to use the molecular subtyping to guide clinical approaches still appears unclear at the moment
and how to use the information on the molecular complexity of each CRC patients for their clinical
management has been addressed poorly in current literature.
We and others have recently shown that multigene panel sequencing, including, but not limited
to, clinically relevant RAS and BRAF hot spots, is a valid, flexible, sensitive and economical method
for the routine diagnostics of mCRC, which may also provide additional information with no extra
costs [25–29]. As a first result of its implementation in the clinical routine for mCRC patients, we report
here on the identification of patterns of molecular alterations predictive of the response to standard
first-line therapies.
2. Results
We investigated whether clinical sequencing with a multigene panel of 22 genes might contribute
to a better molecular characterization and/or improved stratification of mCRC patients.
Our cohort of 77 mCRC patients with features reported in Table 1 had been treated with first
line conventional combination therapy, consisting of FOLFOX/CAPEOX, FOLFIRI or FOLFOXIRI,
eventually associated with monoclonal antibody-mediated targeting of either EGFR or VEGF,
depending on RAS mutational status (Table 1). Patients unfit for combination therapies, because of
their comorbidities and/or age (PS≥ 2), were treated with a therapy adapted to their clinical condition.
Table 1. Characteristics of the study cohort (n = 77).
Characteristics n
Sex
Males 41
Females 36
Age
Mean 64
Range 38–81
Site
Right Colon 28
Left Colon 31
Rectum 18
Metastatic site (n)
Liver 38
Peritoneum 12
Lung 17
Limph nodes 7
Bone 2
First Line Therapy
Chemotherapy/anti-VEGF 47
Chemotherapy/anti-EGFR 18
Chemotherapy 12
Performance Status ECOG
0–1 65
≥2 12
VEGF: Vascular Endothelial Growth Factor; EGFR: Epidermal Growth Factor Receptor; ECOG: Eastern Cooperative
Oncology Group.
We screened this cohort for the presence/absence of mutations in a panel of twenty-two genes,
designed with the OncoNetwork Consortium, including RAS (KRAS/NRAS), EGFR, BRAF, PIK3CA,
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AKT1, ERBB2, PTEN, STK11, MAP2K1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBXW7, FGFR3,
NOTCH1, ERBB4, FGFR1, and FGFR2. The performance of this approach in our hands has been
described elsewhere [25]. The mutation frequency found for each gene (Figure 1) was in line with
previously reported findings [15], indicating that our relatively small cohort was well representative of
the disease. Within this series, two or more mutated genes were found in 59.7% of the patients (46/77),
while 27.3% of the patients (21/77) showed only one mutation. TP53 and RAS mutations were the most
common alterations found (57.1% and 50.6%, respectively). The mutation frequency in other genes was
much lower, being PIK3CA the most frequently mutated (14.3%), followed by FBXW7 (9.1%), BRAF
(9.1%), SMAD4 (7.8%), MET (6.5%), FGFR1 (2.6%). NOTCH1, STK11, EGFR, DDR2, CTNNB1, FGFR3,
PTEN, ERBB4 were mutated in only 1.3% of patients.
Overall, we identified 51 patients carrying actionable gene mutations, as defined by
Chakravarty et al. [30], 22 of which carried druggable alterations (Table 2). The greatest number of
patients (39, 75%) carried RAS mutations, which guided their exclusion from anti-EGFR therapy. Five
patients carried the MSI-H phenotype, predictive of response to anti-immune checkpoint therapy [31].
Importantly, the vast majority of patients positive or negative for actionable mutations also carried
additional oncogenic genetic alterations, which in principle could contribute to an individual clinical
variability affecting responsiveness to standard and target-driven therapies (Table 2). Overlooking this
molecular complexity might be largely responsible for treatment failure, when standard or innovative
targeted approaches are used.
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Figure 1. Mutation frequency for each gene of the panel in the study cohort.
Table 2. List of the genes carrying actionable mutations i the studied metastatic colorectal cancer
(mCRC) patients.
Gene a Status No. of pts (%) No. of pts with Additional Mutation
RAS
WT 38 (49.4) 28 (73.7)
Mut 39 (50.6) 31 (79.5)
BRAF
WT 70 (90.9) 60 (77.9)
Mut 7 (9.1) 6 (85.7)
EGFR
WT 76 (98.7) 66 (85.7)
Mut 1 (1.3) 1 (100.0)
PIK3CA
WT 66 (85.7) 56 (84.8)
Mut 11 (14.3) 10 (90.9)
MET
WT 72 (93.5) 62 (80.5)
Mut 5 (6.5) 5 (100.0)
PTEN
76 (98.7) 66 (85.7)
t 1 (1.3) 1 (100.0)
MSI-H b
No 72 (93.5) 62 (80.5)
Yes 5 (6.5) 5 (100.0)
a: Actionable genes selected according to Chakravarty et al. [30] b: MSI-H status was determined with
appropriate methodology as described in Materials and Methods. All other genetic alterations were detected
by clinical sequencing.
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As a first attempt to take into account this molecular complexity, we subjected our sample to an
unsupervised hierarchical clustering analysis of the mutation patterns, which identified three main
groups (Figure 2). With few exceptions, the first group was characterized by mutations uniquely
occurring in the TP53 and/or RAS genes. This group was named p53/RAS Group (PRG). The second
group was characterized by complete absence of mutations in the 22 genes of the panel and was
named No Mutations Group (NMG). Patients with mutations in at least one of the other genes, with
or without coexisting mutations in TP53 and/or RAS genes, clustered in the third group, which was
named All Genes Group (AGG).
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According to these molecular features, 35 patients (45%) fell into the PRG group, 32 patients (42%)
into the AGG and 10 patients (13%) into the NMG (Figure 3). We then investigated whether these
molecular signatures could predict the response to standard first-line therapies.
Median Progression Free Survival (PFS) in the overall population was 10 months. Of note, patients
belonging to the PRG cluster had a significantly longer PFS than AGG and NMG groups, (12 months,
eight months and six months, respectively; p = 0.0039). The log-rank test showed significant differences
between PRG and AGG curves (p = 0.00735) and PRG vs NMG (p = 0.00431). In contrast AGG and
NMG showed no significant differences (Figure 3). Consistently, stratification into PRG and AGG
was a significant predictor of PFS both at univariate (p = 0.011) and multivariate (p = 0.039) analyses,
independently of the number and nature of other variables included in the analysis, suggesting it is
an independent predictive factor. NMG stratification was a significant predictor of PFS at univariate
(p = 0.010), but it wasn’t at multivariate analyses, likely due to the low number of samples. With the
exception of gender, no other factor significantly affected PFS (Table 3).
To test whether our group stratification could be useful specifically in the RAS WT subset, we
further assessed its impact on PFS on the patients sharing this molecular feature. Consistent with
overall data analysis, stratification into PRG, AGG and NMG was a significant predictor of PFS also in
this subset (Figure S1).
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PFS = progression-free survival; HR = hazard ratio; CI = confidence interval; F = Female; M = Male; RCT=rectum,
RC= right colon; LC=left colon; CHT=chemotherapy.
3. Discussion
NGS is emerging as efficient and cost-effective technology to provide information on
potential clinical utility, since it can track molecular heterogeneity in cancer samples [15,16]. Several
studies suggest that high-throughput NGS testing in metastatic CRC may become a comprehensive
and fast approach to support personalized therapy [32–34] and indicate that recurrent alterations
of a considerable number of pathways and genes are found in CRC. These include the WNT
(APC, β-catenin, MYC), RTKs-MAPK (ERB-Bs, RAS, BRAF, MAPK), PI3K-PTEN, p53, EMT/TGF-β,
mismatch repair, epithelial-mes nchymal transition, immune and inflammation pathways [15,16,35].
Nevertheless, a very limited number of molecular alterati ns gained relevance in the routine clinic l
settings for mCRC, beside RAS/BRAF mutations, and more recently MMR deficiency that predicts a
positive res onse to the immune checkpoint inhibitor pembrolizumab [31]. As a result, only modest
therapeutic advances have been made, and other molecular markers of stablished pr dictive value, to
support the therapeutic choices, are currently missing.
Clinical s quencing of a limited number of genes can now be easily achieved with very reasonable
turnaround time and costs on benchtop instruments [25,29]. Nonetheless, so far very few efforts
have been made to take into account how the molecular compl xit of mCRC impact on the ffi acy
of no l, but al o curr ntly established, therapeutic a proaches. Here, we have used a simplifi d
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NGS-based platform to characterize a cohort of 77 mCRCs patients managed in our cancer clinic and
treated according to standard guidelines for first-line conventional therapy. As expected, this approach
allowed the identification of a relevant number of potentially actionable molecular alterations. Indeed,
39 patients carried RAS mutations, which guided their exclusion from anti-EGFR therapy. Twenty-two
patients were carriers of druggable genetic alterations and five of the MSI-H phenotype, which could
have been taken into account for personalized therapeutic choices. But most important, it also returned
a representation of the molecular complexity of each tumor sample. Rather than taking into account the
clinical impact of individual genomic alterations, or grouping patients based on a supervised pathway
analysis [26,32,34,36,37], we decided to subject our data to an unsupervised hierarchical clustering
analysis, which led us to identify three distinct molecular subgroups (PRG, AGG, NMG). The relatively
small size of our cohort and the high number of different combination therapies in subsequent lines of
intervention did not allow us to efficiently address the effect of this stratification on OS. Nonetheless, it
revealed its utility in predicting PFS in patients treated with different first-line approaches expected to
be equally effective on the base of current literature [14] and NCCN directions (Guideline for treatment
of cancer by site; Colon Guideline Version 4.2018, 19 October 2018 ©National Comprehensive Cancer
Network, www.NCCN.org).
In particular, the best outcome was achieved in PRG patients, exclusively carrying mutations
on TP53 and/or RAS genes. This group of patients is characterized by a minimal number of genetic
alterations (19/35 carried only one mutation either on RAS or TP53). We speculate that this minimal
mutation load on the RTKs-MAPK and/or p53 pathway might be responsible for a higher sensitivity
to standard first-line therapy. Importantly, in the absence of additional genetic alterations, no other
biological intervention could have been possible in this subset. The high prevalence of this group,
representing about half of the total CRCs, probably explains why standard combination therapies have
emerged over the years as the most effective approaches in mCRC patients. By contrast, the AGG
molecular subgroup showed a much worse response compared to patients with exclusive TP53/RAS
mutations. Importantly, 7/32 patients of this group carried the BRAFV600E mutation, an established
bad prognosis marker [22], six of which in association with other mutations and three also associated
with the MSI-H phenotype.
Other 10 patients of this group had mutations in three or more targets, which can be responsible
for the activation of multiple oncogenic pathways. Fourteen out of thirty-two patients of this group
carried mutation on two targets, often involving either RAS or TP53 in different combinations with
other genes, most frequently PIK3CA, SMAD4 and MET. Therefore, the AGG group is characterized by
simultaneous activation of multiple oncogenic pathways, a condition that might reasonably confer
resistance to standard first-line therapy. Importantly, 22 patients in this group were carriers of one or
more druggable molecular alterations, which might have indicated the association with additional
biological agents. For example, we have reported an extended survival in a RAS WT, BRAFV600E
mutation carrier mCRC patient treated with a combination of vemurafenib and panitumumab [20],
suggesting that target-driven combination therapies might significantly improve patient’s outcome.
The target-driven association of anti-EGFR, with either BRAF, PI3K or MET inhibitors could have
improved PFS.
Of relevance, our molecular subgroup stratification predicted PFS also in the RAS WT subset
of patients, where important decisions regarding the biological drug to be employed is currently
dependent on the clinical status of individual patient and treatment intent, rather than molecular
features [14]. Hopefully future studies will help us establish whether our stratification can provide
additional hints for better therapy choices in this subset.
Finally, our data indicate that the standard first-line approaches have limited efficacy in NMG
patients, characterized by the absence of mutations in any of the genes included in the panel. Of
relevance, in silico analysis confirmed a similar percentage of NMG patients in the TCGA CRC dataset
and demonstrated an overall reduced mutation frequency and absence of recurrent point mutations in
particular oncogenic targets, suggesting that either chromosomal rearrangements and/or epigenetic
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events support the tumorigenic programme in this group. These latter observations suggest that
alternative protocols, plausibly hitting alternative molecular mechanism of tumorigenesis, should be
tested in this subgroup of patients, after appropriate molecular investigations have been carried out.
Recently, clinical implications of primary tumor side started to be analyzed in the metastatic
setting, providing evidence that right-sided tumors have a worse prognosis and are less sensitive
to anti-EGFR therapy [38]. Although the limited size of our cohort does not allow us to draw final
conclusions about the impact of side on the predictive value of our results, it is important to recall that
molecular alterations, rather than tumor location, predict outcome at a multivariate analysis in a large
clinical sequencing study on CRC samples [34]. These further stresses our idea that higher attention
should be conveyed on the characterization of the molecular profile of each mCRC case.
Hopefully, the examination of different and much larger molecular and clinical datasets will help
us establishing whether our multigene panel method could provide predictive insights on PFS and OS
for each distinct therapeutic approach, in similar or different clinical settings.
4. Patients and Methods
4.1. Patients and Data Collection
77 FFPE samples were obtained from mCRC patients managed in the clinical routine at Policlinico
Umberto I Hospital (Rome). Patients’ characteristics are listed in Table 1.
Depending on their RAS mutational status, and based on individual features and on the general
algorithm described in [14], patients had been treated with first line conventional combination therapy,
consisting of FOLFOX/CAPEOX (33 patients), FOLFIRI (22 patients) or FOLFOXIRI (10 patients),
associated with monoclonal antibodies-mediated targeting of either EGFR (18 patients) or VEGF
(47 patients). Patients with ECOG performance status ≥2 and thus unfit for combination therapies,
were treated with a therapy adapted to their clinical condition.
All investigations were approved by the Ethics Committee of the University La Sapienza (Prot.:
88/18; RIF.CE:4903, 31-01-2018) and conducted according to the principles outlined in the declaration
of Helsinki.
4.2. DNA Extraction
The tumor cell percentage, estimated by inspecting Haematoxylin–Eosin (H&E) stained slides,
ranged from 20% to 90%. The tumor area was macroscopically dissected to concentrate tumor tissue.
Xylene was added once and ethanol was added twice to remove all paraffin from the tissue sample.
The DNA was extracted using the QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Eluted DNA was quantified with Qubit 2.0 Fluorometer (Thermo
Fisher Scientific, Van Allen Way, Carlsbad, CA, USA) using the Qubit dsDNA HS Assay Kit (Thermo
Fisher Scientific, Eugene, OR, USA).
4.3. IT-PGM Sequencing and Variant Calling
IT-PGM sequencing was achieved as described [25,29]. Approximately 10 ng of DNA was required
to construct barcoded and adaptor-ligated libraries using the Ion AmpliSeq Library Kit 2.0 (Thermo
Fisher Scientific, Van Allen Way, Carlsbad, CA, USA) and Ion Xpress™ Barcode Adapter 1-16 Kit
(Thermo Fisher Scientific). The samples were analyzed using the Ion AmpliSeq Colon and Lung Cancer
Research Panel V2 (Thermo Fisher Scientific, Guilford, CT, USA) containing a single primer pool to
amplify hotspots and targeted regions of 22 cancer genes frequently mutated in CRCs and NSCLCs.
Templated spheres were prepared using 100 pM of each library using the Ion One Touch 2.0 machine
(Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA 92008, USA). Template-positive spheres were
loaded into Ion chip 314 or Ion chip 316 and sequenced by IT-PGM machine (Thermo Fisher Scientific,
Van Allen Way, Carlsbad, CA 92008, USA). Sequencing data were analyzed with the Ion Torrent
Suite (Thermo Fisher Scientific, https://github.com/iontorrent/TS). Variants with a quality <30 were
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filtered out. PolyPhen-2 (Polymorphism Phenotyping v2; http://genetics.bwh.harvard.edu/pph2/),
SIFT (Sorts Intolerant from Tolerant substitutions; http://provean.jcvi.org/protein_batch_submit.php?
species=human) and PROVEAN (Protein Variation Effect Analyzer, http://provean.jcvi.org/protein_
batch_submit.php?species=human) computational tools were used to predict the possible impact of
each genetic change on the function of the corresponding protein.
4.4. Bioinformatic and Statistical Analysis
Mutational profile detected for each of the 77 mCRC samples was analyzed through heat-map
representation. We considered a value equal to 0 for the wild-type gene and value equal to one
corresponds to a mutated gene. In order to perform cluster analysis, we chose the hierarchical
agglomerative clustering procedure, which has a bottom-up approach. Complete linkage method and
a Euclidean distance metric for hierarchical clustering were used. This clustering method defines the
distance between two clusters as the maximum distance between their individual components. At
every stage of the clustering process, the two nearest clusters are merged into a new cluster. The process
is repeated until the whole data set is agglomerated into one single cluster. Hierarchical clustering of
samples and genes was performed with the “heatmap.2” R function by employing “gplot” packages.
The Kaplan–Meier estimator was computed with “survfit” R function by employing “survival”
package [39]. The log-rank test was used to test differences between groups. A Cox-regression
model was applied to the data with a univariate and multivariate approach. Variables considered in
the univariate analysis were mutational stratification, gender, age, tumor location, grading, adjuvant
therapy, first line therapy, metastatic site, ECOG PS and surgery for the primary site.
4.5. Determination of MSI-H phenotype
Determination of MSI status was carried out by analysis of BAT25, BAT26, NR21, NR22 and NR24
mononucleotide repeats as previously described [40]. Briefly, one PCR primer of each pair was labelled
with either FAM, HEX, or NED fluorescent markers. PCR amplification was performed under the
following conditions: Denaturation at 94 ◦C for five minutes, 35 cycles of denaturation at 94 ◦C for
30 s, annealing at 55 ◦C for 30 s, and extension at 72 ◦C for 30 s. This was followed by an extension
step at 72 ◦C for 7 min. PCR products were run on ABI PRISM 3130xl Genetic Analyzer (16 capillary
DNA sequencer, Applied Biosystems). Gene Mapper software 5 (version 5.0, Applied Biosystems, Van
Allen Way, Carlsbad, CA, USA) was used to calculate the size of each fluorescent PCR product. Five
out of seventy-seven tumors showed MSI-H phenotype when deletions in all five mononucleotide
markers were found.
5. Conclusions
The response of mCRC to the first-line conventional combination therapy is highly variable,
reflecting the elevated heterogeneity of the disease. By a simplified NGS approach and assisted by
bioinformatic analysis, we identified three molecular subgroups in a cohort of 77 mCRC patients
characterized by three different mutation profiles. This new, handy, and cost-effective NGS-based
stratification significantly predicts clinical responses to first-line conventional combination therapy
in mCRC.
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